|Committee Member||Employment||Consultant||Speakers Bureau||Ownership/Partnership/Principal||Personal Research||Institutional, Organizational or Other Financial Benefit||Expert Witness|
|David M. Reboussin (Chair)||Wake Forest School of Medicine—Professor, Department of Biostatistics||None||None||None||None||None||None|
|Norrina B. Allen||Northwestern University Feinberg School of Medicine—Assistant Professor, Department of Preventive Medicine||None||None||None||None||None||None|
|Michael E. Griswold||University of Mississippi Medical Center—Professor & Chair, Department of Data Science||None||None||None||None||None||None|
|Eliseo Guallar||Johns Hopkins Bloomberg School of Public Health—Professor, Department of Epidemiology||None||None||None||None||None||None|
|Yuling Hong||Centers for Disease Control and Prevention, National Center for Chronic Disease Prevention and Health Promotion—Associate Director of Science, Division for Heart Disease and Stroke Prevention||None||None||None||None||None||None|
|Daniel T. Lackland||Medical University of South Carolina—Professor of Epidemiology, Department of Neurology; Director, Division of Translational Neurosciences and Population Studies||None||None||None||None||None||None|
|Edgar (Pete) R. Miller III||Johns Hopkins University—Professor of Medicine||None||None||None||None||None||None|
|Tamar Polonsky||University of Chicago—Assistant Professor, Section of Cardiology||None||None||None||None||None|
|Angela M. Thompson-Paul||Centers for Disease Control and Prevention, National Center for Chronic Disease Prevention and Health Promotion—Epidemiologist, Division of Heart Disease and Stroke Prevention||None||None||None||None||None||None|
|Suma Vupputuri||Kaiser Permanente Mid-Atlantic States—Research Scientist, Mid-Atlantic Permanente Research Institute||None||None||None||None||None|
This table represents the relationships of committee members with industry and other entities that were determined to be relevant to this document. These relationships were reviewed and updated in conjunction with all meetings and/or conference calls of the writing committee during the document development process. The table does not necessarily reflect relationships with industry at the time of publication. A person is deemed to have a significant interest in a business if the interest represents ownership of ≥5% of the voting stock or share of the business entity, or ownership of ≥$5000 of the fair market value of the business entity; or if funds received by the person from the business entity exceed 5% of the person’s gross income for the previous year. Relationships that exist with no financial benefit are also included for the purpose of transparency. Relationships in this table are modest unless otherwise noted. According to the ACC/AHA, a person has a relevant relationship IF: a) the relationship or interest relates to the same or similar subject matter, intellectual property or asset, topic, or issue addressed in the document; or b) the company/entity (with whom the relationship exists) makes a drug, drug class, or device addressed in the document, or makes a competing drug or device addressed in the document; or c) the person or a member of the person’s household, has a reasonable potential for financial, professional or other personal gain or loss as a result of the issues/content addressed in the document. Please refer to http://www.acc.org/guidelines/about-guidelines-and-clinical-documents/relationships-with-industry-policy for definitions of disclosure categories or additional information about the ACC/AHA Disclosure Policy for Writing Committees.
AAPA indicates American Academy of Physician Assistants; ABC, Association of Black Cardiologists; ACC, indicates American College of Cardiology; ACPM, American College of Preventive Medicine; AGS, American Geriatrics Society; AHA, American Heart Association; APhA, American Pharmacists Association; ASH, American Society of Hypertension; ASPC, American Society for Preventive Cardiology; ERC, evidence review committee; NMA, National Medical Association; and PCNA, Preventive Cardiovascular Nurses Association.
↵∗ Indicates significant relationship.
↵† Dr. Vupputuri entered into a relationship as a subcontracted co-investigator on July 5, 2017 via the MidAtlantic Permanente Research Institute and the Center for Health Research at Kaiser Permanente Northwest, as part of a retrospective cohort study funded by Sanofi, Inc. The contract itself was between the MidAtlantic Permanente Research Institute and the Center for Health Research at Kaiser Permanente Northwest. Although funding was processes via two research organizations, this was still considered to be “RWI” and is thus listed in the disclosure table. At this time, the ERC had already worked approximately three years, and all data gathering, analyses, and conclusions had already been formulated. Nevertheless, relevant analyses and sections of the ERC report were independently scientifically reviewed by David M. Reboussin, Norrina B. Allen, Daniel T. Lackland, Michael E. Griswold, Edgar (Pete) R. Miller III, Eliseo Guallar, Yuling Hong, and Angela M. Thompson-Paul, and this review and the finalized ERC report were then re-vetted and voted on for endorsement by the ERC and the hypertension guideline writing committee.
↵‡ On March 1, 2018 (after publication of this Systematic Review), Dr. Polonsky, after having reviewed her listing on the CMS Open Payments Data website, realized that she had been a local PI in the STRENGTH trial, supported by AstraZeneca, and promptly reported this to the Task Force. Only 1 patient was recruited and Dr. Polansky did not receive any direct salary support, but by ACC/AHA standards, this would constitute a relationship with industry (RWI) and thus, in the interest of full transparency, this footnote has been added.